S everal lines of evidence have suggested that oxidized low density lipoprotein (Ox-LDL) plays a pivotal role in the pathogenesis of atherosclerosis. 1, 2 Ox-LDL and its lipid constituents appear to modulate endothelial functions that are relevant to atherogenesis. [3] [4] [5] [6] Vascular endothelial cells in culture and liver sinusoidal endothelial cells have been shown to take up modified forms of LDL, including Ox-LDL. [7] [8] [9] [10] [11] Although several different molecules, such as class A macrophage scavenger receptors, 12, 13 CD36, 14 SR-BI, 15 MARCO, 16 and macrosialin (CD68), 17 have been identified to support Ox-LDL uptake in macrophages; molecular mechanisms involved in endothelial uptake of Ox-LDL remain to be fully clarified. 18, 19 Using expression cloning strategy, we recently have identified a novel molecule, designated lectin-like Ox-LDL receptor-1 (LOX-1) in cultured bovine aortic endothelial cells. 20 LOX-1 is a 50-kDa type II membrane glycoprotein whose structure belongs to the C-type lectin family and does not share any structural homology with other known molecules that can act as a receptor for Ox-LDL. 20 LOX-1 also is expressed in arterial endothelial cells in humans in vivo, suggesting that LOX-1 may play an important role in the pathogenesis of atherogenesis and vascular diseases. 20 Scavenger receptors, in general, have been shown to exhibit broad ligand specificity. They can recognize modified forms of LDL, such as Ox-LDL, Ac-LDL, and maleylated LDL, as well as 4-stranded nucleic acids (polyinosinic acid), polysaccharides (dextran sulfate, fucoidin), and phospholipids (phosphatidylserine). 18 Recent reports also have shown that some of the scavenger receptors can take up advanced glycosylation end products, 21 oxidatively damaged erythrocytes, 22 apoptotic cells, 23 lipopolysaccharide, 24 and betaamyloid. 25 In this report, we show ligand specificity of this novel Ox-LDL receptor, LOX-1, by use of Chinese hamster ovary K1 (CHO-K1) cells stably expressing bovine and human LOX-1.
Methods

Materials
Polyinosinic acid (poly I), polycytidylic acid (poly C), fucoidin, carrageenan (type III Kappa), chondroitin sulfate A, and n-octyl-␤-D-glucopyranoside (octyl glucoside) were purchased from Sigma. Lipoperoxide test kits for thiobarbituric acid reactive substances (TBARS) were obtained from Wako Pure Chemical. Agarose gel plates and running buffer for electrophoretic mobility of lipoproteins were purchased from Helena laboratories. Reagents for enzymatic determination of total cholesterol were purchased from Toyobo.
Lipoprotein and Ligand Preparations
Human LDL (1.019 to 1.063 g/mL) was isolated from the plasma of healthy human subjects by sequential ultracentrifugation at 4°C. LDL was dialyzed against 3 changes of LDL buffer (150 mmol/L NaCl; 0.24 mmol/L EDTA; pH 7.4) for 36 hours at 4°C, filtered through 0.45-m filters, and stored at 4°C. After extensive dialysis against 3 changes of PBS for 36 hours at 4°C, oxidative modification of LDL was performed by incubating with 7.5 mol/L CuSO 4 at 37°C for 24 hours. 7 Acetylation of LDL was achieved by repeated additions of acetic anhydride as previously described. 26 Ox-LDL and acetylated LDL (Ac-LDL) were dialyzed against 3 changes of LDL buffer for 36 hours at 4°C. Modification of LDL was monitored by electrophoretic mobility relative to native LDL expressed as relative electrophoretic mobility (REM; arbitrary unit). REM for Ox-LDL and Ac-LDL were 2.20Ϯ0.11 (nϭ5) and 2.23Ϯ0.21 (nϭ5), respectively. Oxidation of LDL was further monitored by the amounts of lipid peroxides by measuring TBARS. Values for TBARS in Ox-LDL, Ac-LDL, and native LDL were 9.76Ϯ1.34 nmol (nϭ6), 1.68Ϯ0.60 nmol (nϭ2), and 1.15Ϯ0.21 nmol (nϭ2) of MDA/mg protein, respectively. Ox-LDL and Ac-LDL were radiolabeled with Na 125 I (DuPont) by the iodine monochloride method previously described. 26 Maleylated BSA (M-BSA) was prepared as described previously. 27 Protein concentrations were determined by the method of Lowry et al.
Cell Culture and Stable Transfection
CHO-K1 cells were cultured in Ham's F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS, Irvine Scientific), 100 U/mL penicillin, and 100 g/mL streptomycin (medium A) at 37°C in a humidified air with 5% CO 2 . A bovine LOX-1 (BLOX-1) expression vector, designated pBLOX-1 (1 g) was cotransfected with pSV2bsr (10 ng) (Funakoshi) into CHO-K1 cells by calcium phosphate transfection method. 20 Colonies resistant to blasticidin S in medium B (medium A containing 10 g/mL of blasticidin S) were screened by intracellular uptake of fluorescent DiI-labeled Ox-LDL (5 g/mL for 2 hours in medium B) to identify BLOX-1-positive cells. One of these positive cells was picked and used as stable transformant of BLOX-1 (BLOX-1-CHO). A CHO-K1 cell line stably expressing human LOX-1, which is a human homolog of BLOX-1, was also established (HLOX-1-CHO). A CHO-K1 cell line stably expressing murine class A scavenger receptor type II (mSR-II-CHO) was kindly provided by Dr Tatsuhiko Kodama (University of Tokyo, Japan).
Binding and Degradation of 125 I-Labeled Lipoproteins
Binding of 125 I-Ox-LDL and 125 I-Ac-LDL to BLOX-1-CHO, HLOX-1-CHO, mSR-II-CHO, and nontransfected CHO-K1 (control CHO) was measured after incubation in 12-well culture dishes at 4°C as previously described. 28 In brief, after washing 3 times with PBS, adherent cells were prechilled in 1 mL ice-cold DMEM supplemented with 10 mmol/L HEPES-NaOH (pH 7.4) and 10% (v/v) FBS (medium C) for 30 minutes at 4°C. Culture media were then removed and replaced with 0.5 mL of medium C containing the indicated amounts of ligands. After incubation at 4°C for 2 hours, the conditioned media were removed, and the cells were washed rapidly 3 times with Tris washing buffer (50 mmol/L Tris-HCl; 150 mmol/L NaCl; pH 7.4) containing 2 mg/mL of BSA, followed by 2 washes for 10 minutes and 2 rapid washes with Tris washing buffer without BSA. The cells were then dissolved in 0.5 mL of 0.2 N NaOH for 3 to 4 hours on a shaker, and the radioactivity associated with cells was measured by a gamma counter. Proteolytic degradation of 125 I-labeled lipoproteins was carried out as previously described. 29 In brief, cells were incubated with ligands in medium C at 37°C for 4 to 6 hours, and radioactivities in trichloroacetic acid (TCA)-soluble, chloroform-unextractable fractions in the cell-conditioned media were measured. Each value obtained from medium incubated with lipoproteins without cells was subtracted from that obtained from cell-conditioned medium incubated with lipoproteins.
Delipidation of Lipoproteins
Ox-LDL and 125 I-Ox-LDL were delipidated by the method of Bligh and Dyer as described by Parthasarathy et al. 30 The apolipoprotein was solubilized in an aqueous solution using octyl glucoside (6.0 mg/mL, 30 times more than protein concentration). Any turbidity usually was cleared by the addition of NaOH. The solution was dialyzed immediately against PBS for 24 hours at 4°C. To confirm that delipidation was completed, cholesterol content of delipidated Ox-LDL (Ox-apoB) and untreated Ox-LDL was measured by an enzymatic assay. Cholesterol was undetectable in delipidated Ox-LDL samples.
Results
LOX-1 Binds and Degrades Ox-LDL but Not Ac-LDL
Dose-response relationship in
125 I-Ox-LDL binding to BLOX-1-CHO showed saturation kinetics (Figure 1) , and Scatchard analysis revealed that 125 I-Ox-LDL can bind to bovine LOX-1 with an approximate dissociation constant (Kd) of 36 g/mL (Figure 1, inset) . This result indicates that LOX-1 can bind Ox-LDL with relatively lower affinity than that (Kd Ͻ10 g/mL) in Ox-LDL binding to class A scavenger receptors. 31 To examine whether LOX-1 also can recognize Ac-LDL, binding and proteolytic degradation of 125 I-labeled lipoproteins in BLOX-1-CHO were examined. As shown in Figure  2A , BLOX-1-CHO showed prominent binding of 125 I-labeled Ox-LDL as compared with control CHO. In contrast, binding of 125 I-Ac-LDL to BLOX-1-CHO was not significantly different from that in control CHO (Figure 2A ). Proteolytic degradation of 125 I-Ox-LDL in BLOX-1-CHO showed similar results with those observed in binding studies ( Figure 2B ). Amounts of 125 I-Ac-LDL degraded in BLOX-1-CHO were not significantly different from those in control CHO ( Figure  2B ). Furthermore, as previously reported, both binding and degradation of 125 I-Ox-LDL were significantly displaced by a 50-fold excess amounts of Ac-LDL and Ox-LDL in mSR-II-CHO ( Figure 3B ). Addition of 50-fold excess amounts of unlabeled Ox-LDL abolished binding and degradation of 125 I-Ox-LDL to BLOX-1-CHO by 74% and 86%, respectively. However, the same concentration of unlabeled Ac-LDL or native LDL 20 did not block the binding and degradation of 125 I-Ox-LDL to BLOX-1-CHO ( Figure 3A ). These results demonstrate that LOX-1 is a receptor for Ox-LDL but not for Ac-LDL.
Effects of Pharmacological Competitors on Ox-LDL Binding to LOX-1
To characterize ligand specificity of LOX-1, effects of various pharmacological competitors, which have been shown to inhibit Ox-LDL binding to class A and B scavenger receptors, on 125 I-Ox-LDL binding to BLOX-1-CHO were examined. As previously reported, optimal concentrations of polyanions, such as poly I, carrageenan, fucoidin, and M-BSA, inhibited 125 I-Ox-LDL binding to mSR-II-CHO by Ͼ90% ( Figure 4A ). In contrast, no inhibitory effect of fucoidin or M-BSA on 125 I-Ox-LDL binding to BLOX-1-CHO was observed (5% and 8% inhibition, respectively; Figure 4A ). Poly I and carrageenan abolished 125 I-Ox-LDL binding to BLOX-1-CHO by 62% and 60%, respectively, which was comparable with the inhibitory effect of excess amounts of unlabeled Ox-LDL (74% inhibition; Figure 4A ). Competition studies in proteolytic degradation assays gave similar results with those found in binding assays ( Figure 4B ). Although poly I, carrageenan, fucoidin, and M-BSA significantly inhibited the degradation of 125 I-Ox-LDL in mSR-II-CHO, fucoidin and M-BSA had no inhibitory effect on 125 I-Ox-LDL degradation in BLOX-1-CHO. In contrast, poly I and carrageenan inhibited degradation of 125 I-Ox-LDL by 70% and 50%, respectively in BLOX-1-CHO ( Figure 4B ). 
LOX-1 Binds to Protein Moiety of Ox-LDL
To define an epitope(s) on Ox-LDL particles recognized by LOX-1, binding and degradation of delipidated Ox-LDL (Ox-apo B) in BLOX-1-CHO, as well as in HLOX-1-CHO, were examined. BLOX-1-CHO was able to bind delipidated 125 I-Ox-apoB almost equally to untreated 125 I-Ox-LDL ( Figure  5A ). Furthermore, binding of both 125 I-Ox-LDL and 125 I-OxapoB to BLOX-1-CHO was equally inhibited by a 50-fold excess amount of unlabeled Ox-LDL (by 66% and 42%, respectively) as well as unlabeled Ox-apoB (by 75% and 66%, respectively; Figure 5A 
Discussion
Cellular uptake and subsequent proteolytic degradation of Ox-LDL in vascular endothelial cells, as well as macrophages and activated smooth muscle cells, appear to play a key role in atherogenesis. 1, 2, 6 Previous studies have identified several classes of receptors for Ox-LDL that exhibit a broad spectrum of ligand specificities. The present study, therefore, sought to define ligand specificities of LOX-1, because this novel receptor for Ox-LDL does not share any structural homology with other known receptors for Ox-LDL. Progression of oxidative modification of LDL is followed by generation of lipid peroxides. During lipid peroxidation, reactive aldehydes form Schiff bases with lysine residues on apolipoprotein B-100 and thereby increase the negative charge of LDL particles. 32 Thus, negative charges on LDL particles produced during oxidative modification appear to facilitate binding to the positively charged collagen-like domain of class A scavenger receptors. Furthermore, class A scavenger receptors can recognize a wide spectrum of negatively charged macromolecules including Ox-LDL and Ac-LDL. 12, 13, 18, 24, 25, 33 The present data with CHO-K1 cells that stably express LOX-1, however, show that LOX-1 can bind and degrade comparable amounts of Ox-LDL but not significant amounts of Ac-LDL. Moreover, binding and degradation of Ox-LDL in these cells can be blocked effectively by poly I and carrageenan but not by fucoidin or M-BSA. Taken together, interactions between Ox-LDL and LOX-1 cannot be explained simply by negative charges of Ox-LDL particles but rather depend on other molecular mechanisms.
Class A scavenger receptors recognize epitopes on apoprotein B-100 of modified LDL. 30 CD36, in contrast, does not bind delipidated Ox-LDL, indicating that CD36 recognizes the lipid portion of Ox-LDL but not oxidized apolipoprotein B-100. 34 As shown in this study, LOX-1 appears to bind to the protein portion of Ox-LDL. Our studies cannot exclude completely the possibility that LOX-1 may recognize certain lipids that are firmly linked to apolipoprotein B-100 and therefore was not able to be extracted by organic solvents; however, these results clearly indicate that molecular mechanisms of Ox-LDL binding to LOX-1 are distinct from those of class B scavenger receptors, such as CD36 and SR-BI.
Because LOX-1 has a lectin-like structure in the extracellular domain, like selectins, certain sugar chains on oxidatively modified apolipoprotein B-100 might be responsible for binding to LOX-1. Our preliminary experiments, however, failed to show any significant inhibition in Ox-LDL binding to BLOX-1-CHO by oligosaccharides that have been shown to bind to selectins (data not shown). Further studies are necessary to elucidate molecular mechanisms involved in binding and internalization of Ox-LDL by LOX-1, which has a simple C-type lectin-like structure. Moreover, scavenger receptors, in general, have been shown to bind a variety of pathophysiological ligands, such as oxidized RBC, 22 apoptotic cells, 21 advanced glycosylation end products, 23 lipopolysaccharide, 24 and beta-amyloid. 25 Studies in progress in our laboratory will determine whether LOX-1 can act as a receptor for these ligands.
In summary, this article demonstrates the unique ligand specificity of LOX-1, a novel endothelial receptor for Ox-LDL. Elucidation of molecular mechanisms involved in receptor-ligand interactions of LOX-1 may provide a new therapeutic target in atherogenesis and vascular diseases.
